Cytonics Corporation

Mar 25, 2025

Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development

Jan 21, 2025

Cytonics Announces Successful Completion of Phase 1 Study for First Nine Patients in CYT-108 Clinical Trial

Sep 06, 2024

Cytonics Announces Completion Of Enrollment For Phase 1 Clinical Study Evaluating CYT-108, A Novel Recombinant Protease Inhibitor, In Patients Suffering From Osteoarthritis Of The Knee

Jul 15, 2024

Cytonics Announces Initiation Of First-In-Human Phase 1 Clinical Study For CYT-108 In Patients Suffering From Osteoarthritis Of The Knee